Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 3/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2436105 | 0.88 | EGLN1 (0.52) | ALDH1A1KDM4ECYP1A2EGLN1LMNA | |
| SCHEMBL337676 | 0.87 | ALDH1A1 (0.58) | ALDH1A1KDM4EHTTLMNAGAA | |
| SCHEMBL2437605 | 0.78 | ALDH1A1 (0.48) | ALDH1A1CYP1A2CYP2C9CYP2C19TNF | |
| SCHEMBL336460 | 0.76 | EGLN1 (0.55) | EGLN1 | |
| SCHEMBL10084718 | 0.74 | MEN1 (0.45) | KDM4EEGLN1HTTTSHR | |
| SCHEMBL14047689 | 0.71 | EGLN1 (0.37) | ALDH1A1KDM4EEGLN1LMNAMAPT | |
| SCHEMBL2438136 | 0.71 | EGLN1 (0.52) | ALDH1A1CYP1A2EGLN1LMNAMAPT | |
| SCHEMBL2441366 | 0.70 | EGLN1 (0.56) | ALDH1A1KDM4EEGLN1LMNA | |
| SCHEMBL336498 | 0.70 | EGLN1 (0.51) | EGLN1 | |
| SCHEMBL10080871 | 0.69 | ALDH1A1 (0.55) | ALDH1A1KDM4EHTTLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142509-B1 | QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8349868-B2 | Azaquinolones that inhibit prolyl hydroxylase | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8048894-B2 | Quinolones and azaquinolones that inhibit prolyl hydroxylase | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110224248-A1 | AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC. (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2142509-A2 | QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | Amgen, Inc (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090156605-A1 | Quinolones and azaquinolones that inhbit prolyl hydroxylase | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008130600-A2 | QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156605-A1 | Quinolones and azaquinolones that inhbit prolyl hydroxylase | EGLN3, HIF1AN, EGLN2 | ALDH1A1 191/4885KDM4E 336/4885CYP1A2 41/4885 |
| US-20110224248-A1 | AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | HIF1AN, EGLN3, EGLN2 | ALDH1A1 145/4885KDM4E 126/4885CYP1A2 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.